Norman B. Gaylis
NORMAN B. GAYLIS, M.D., F.A.C.P., F.A.C.R
Norman B. Gaylis is recognized as one of the country’s leaders in the field of arthritis and rheumatic diseases. He is board-certified in Internal Medicine and Rheumatology and has been a practicing Rheumatologist in the greater Miami area for more than 35 years. Dr. Gaylis was born in Johannesburg, South Africa and completed his training as a rheumatologist at the University of Miami where he served on the clinical faculty for many years. Dr. Gaylis has presented numerous scientific papers and has conducted medical meetings around the United States and internationally. He is the author of multiple peer reviewed articles, in particular on the subjects of rheumatoid arthritis, magnetic resonance imaging in rheumatology and other rheumatic disorders.
In addition to his clinical practice, he was the past Medical Director for the Rheumatology division at Cardinal Health and is a speaker and consultant for numerous pharmaceutical companies. Dr. Gaylis is the Medical Director of AARDS Research, Inc., a clinical research organization specializing in clinical research trials for autoimmune diseases and the Medial Director of Infusion and Immunotherapy Center of South Florida (IIC.) He has been a Principal Investigator in over 150 clinical trials for new pharmaceutical products for the treatment of Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus, Lupus Nephritis, Gout, and Sjogren’s syndrome.
The recipient of many awards and honors, Dr. Gaylis is an active member of the American College of Rheumatology (ACR) and is currently serving as a Board Member. Dr. Gaylis is a 2017 recipient of the Master of the ACR Designation. Recognition as a Master is one of the highest honors that the College bestows on its distinguished members.
He is a past Board member of the Rheumatology Research Foundation. As part of his commitment to clinical research, he has recently established an endowment (Norman B Gaylis, MD Research Award for Rheumatologists in Community Practice) for the Rheumatology Research Foundation to award annually for the exclusive support of research by rheumatologists in clinical practice. He strongly believes in the benefits of clinical research breaking the ground for new treatments and the viability of rheumatologists in the future of healthcare.
He is one of the founders and is a Past President of the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR). He is also a past president of the Florida Society of Rheumatology.
He has been featured in the Wall Street Journal, on multiple television news shows, and for many years was also the host of HEALTH TALK, a medical talk show on the radio in South Florida. He is also on the Editorial Board of Rheumatology News for which he has contributed numerous articles.
Medical School:University of Witwatersrand
Johannesburg, South Africa
(6 year program) 1967 – 1973
Clinical: University of Witwatersrand Rotating Internship 1974 – Surgery, Orthopedics, Internal Medicine. Medical Registrar, Johannesburg General Hospital 1975 – 6 months
Pathology Registrar at South African Institute for Medical Research 1975 – 12 months.
United Kingdom: Medical House Officer at Guys Hospital and Harley Street Clinic 1976 – 6 months.
Internal Medicine Residency at Mt. Sinai Medical Center, Miami Beach, Florida
Residency, June 30-1976 – June 30, 1977
Chief Medical Resident, July 1, 1978 – June 30, 1979
Department of Rheumatology, University of Miami Medical School, Miami, Florida,
July 1, 1979 – June 30, 1981
Arthritis and Rheumatic Disease Specialties
Aventura, FL, 33180. Private Practice of Rheumatology, Medical Director Clinical Laboratory Norman B Gaylis, MD, June 30, 1981 – Present
AARDS Research, Inc., Arthritis & Rheumatic Disease Specialties Research Medical Director and Primary Investigator April 2010-present
Infusion and Immunotherapy Center of South Florida (IIC), Medical Director September,2014-present
Medical Director Rheumatology, Cardinal Health Specialty Solutions 2010-2013
Chief Operating Officer of Rheumatology, Continucare Corporation 1996 – 1999
Chief Operating Officer of Rheumatology Physicians Practice Division, Sheridan Healthcare 1992
Founder and Director of Miami Arthritis Center 1985-1999
- Rheumatology Medical Director International Physicians Network 2020 to present
- Scientific Board of CytoDyn Inc. 2020-present
- Scientific Board Inmedix, Inc. 2020-present
- Board of Directors American College of Rheumatology (ACR) 2019- present
- Board of Directors Rheumatology Research Foundation 2018-2019
- Board of Directors ICAMRL 2012-2016
- Editorial Board, Rheumatology News 2008-Present
- President of International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) 2008-2010
- American College of Rheumatology Research and Education Foundation 2006-2010
- President of International Society for Musculoskeletal Imaging in Rheumatology(ISEMIR) 2008-2010
- Program Chair for International Society for Musculoskeletal Imaging in Rheumatology(ISEMIR) 2007-2010
- Clinical Associate Professor of Medicine Department of Rheumatology University of Miami, 1992 – 2002
- President Florida Society of Rheumatology, 1992, 1994
- Physician Ad. Committee Medicare BCBS-Florida 1992 – 1994
- Program Chairman – Florida Society of Rheumatology, 1989 – 1991
- Executive Member of Committee of Rheumatologic
Care, American College of Rheumatology, 1986-
1990 - Member of Marketing Committee of American College of Rheumatology, 1987 – 1989
- Florida Representative on American College of Rheumatology Committee of Rheumatologic Care1985, 1986 and 1987
- Fellow American College of Physicians, 1984
American Board of Internal Medicine 1979 No.73208.
American Board of Rheumatology November 1983 ME31090.
ECFMG 1972 No. 20098274.
Flex 1978 No. 192529.
The Financial Impact of Covid-19 on Rheumatology Practices The Rheumatologist Sep 2020
Safety and efficacy of neurostimulation with a miniaturized vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomized pilot study. Lancet, July 2020
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis ACR 2018
Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-Up Dosing of Tofacitinib in a Treat To Target Approach. ACR/AHRP, San Diego, CA 2017
Patient Perspectives on Intravenous Biologics for Rheumatologic Disease
Patient Perspectives on Intravenous Biologics for Rheumatologic Disease
Covergent Validity of New Disease Assessment Instruments in Systemic Lupus Erythematosus in Relation to SLEDAI-2K. ACR/AHRP, San Francisco, CA 2015.
Safety of Infusing Rituximab. BMC Musculoskeletal Disorders, 2014
Results from the RATE-RA Study: A Multicenter, Single-Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis. ACR/AHRP San Diego, October 2013.
Results from the Rate – RA Study. A Multicenter Open-Label, Single-Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis.
EULAR, Madrid, Spain June 2013
Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial
EULAR, Madrid, Spain June 2013
Key Changes in Health Care. Rheumatology Advisory Board Meeting, March 2013
5th Annual Int’l Society Musculoskeletal Imaging. Volume 42, Number 4, February 2013
Evaluating Joint-Space Narrowing and Cartilage Loss in Rheumatoid Arthritis by Using MRI. Arthritis Research Therapy, May 2012.
Comparison of 1.5T Whole-Body MRI and 0.2T Extremity MRI for Monitoring Rheumatoid Arthritis in a Multi-Site Clinical Trial (IMPRESS) EULAR, London, England, May 2011
Both High and Low Field MRI Correlate With Clinical Assessments and Biomarkers in Patients With Active Moderate to Severe Rheumatoid Arthritis EULAR , London, England 2011
Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-TNF Alpha Agents: 2 Year Results from Go-After Study, EULAR, Rome, Italy, June 2010
MRI Findings Correlate with Clinical Assessments and Biomarkers in Patients with Active Moderate or Severe Rheumatoid Arthritis, EULAR, Rome, Italy, June 2010
Retreatment with Rituximab Based on a Treatment to Target Approach Provides Better Disease Control than Treatment as Needed in Patients with RA, EULAR, Rome, Italy, June 2010
Discriminative Power of Different Combinations of Bones and Joints for Assessing Change in Rheumatoid Arthritis with MRI: Results Based on Pooled Data from Four Multisite Clinical trials. ACR/ACHP, Atlanta, GA 2010
Retreatment with Rituximab (RTX) Based On a Treatment to Target (TT) Approach Provides Better Disease Control Than Treatment as Needed (PRN) in Patients (pts) with Rheumatoid Arthritis (RA), ACR Annual Meeting, Philadelphia, PA October 2009
Strategies For Improving Treatment Outcomes, October 2009
Randomised, Double-Blind, Placebo-Controlled, Phase III Trial. The Lancet, June 2009.
Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-TNFα Agents (GO-AFTER Study): Week 52 Results, ACR Annual Meeting, Philadelphia, PA 2009
Evaluating Osteitis in Rheumatoid Arthritis with Gadolinium-enhanced MRI. ACR, San Francisco, CA 2008
Golimumab, a Human Anti-TNFα Monoclonal Antibody, Injected Every 4 Weeks: Efficacy & Safety in RA Patients Previously Treated with Anti-TNFα Agents (GO-AFTER Study). ACR, San Francisco, CA 2008
Adding Extremity MRI to Your Practice. Rheumatology News. Volume 8, Number 8, August 2008
Efficacy, Safety, And Dose Frequency Of Retreatment With Rituximab in RA: Results From A Randomized Controlled Trial (SUNRISE) ACR, San Franciso, CA 2008
Rheumatology And Infusion Therapy: Practice and Treatment Choices in the New Era, A Series of
Interactive CME Discussions The Foundation for Better Health Care (FBHC), 2007
Image of the Month. Rheumatology News, Volume 6, No.12, December 2007
Image of the Month. Rheumatology News, Volume 6, No. 10., October 2007
Extremity Imaging Improves RA Care. Rheumatology News, Volume 6, No. 9., September 2007
Inflammatory, B Cartilage markers correlated with Efficacy, EULAR, Amsterdam, Netherlands 2006
Open, Randomized Study of Rheumatoid Arthritis Patients switched from Etanercept: Changes in Serum
Adalimumab Efficacy in Psoriatic Arthritis Patients Oligoarticular Arthritis: Sub analysis of Adept, EULAR, Amsterdam, Netherlands 2006
Comparison of Two Different In-Office 0.2T Magnetic Imaging Systems and Standard Radiographs in an Outpatient Rheumatoid Arthritis Patient Population, EULAR, Amsterdam, Netherlands 2006
Infliximab Provides Additional Clinical and Radiographic Benefits in RA Patients Who Have an Inadequate Response to Etanercept, EULAR, Vienna, Austria 2005
Changes in Erosive Status Detected on In-Office MRI after One Year Follow-up of Rheumatoid Arthritis Patients on Infliximab Therapy, EULAR, Vienna, Austria 2005
Comparison of In-Office MRI Versus Conventional Radiography In Detecting Changes In Erosions after One Year Follow-up Exams in Rheumatoid Arthritis Patients on Infliximab Therapy, EULAR, Vienna, Austria 2005
Effects of Cycloxygenase-2 (COX-2) Selective Inhibitor Non-steroidal Anti-Inflammatory Agents on Bone Mineral Density, ISCD, New Orleans, 2005
Rheumatoid Arthritis the Present and the Future Pacifico Yokohama, Japan 2005
JCR Congress of Rheumatology, Guest Speaker
The Many Facets of Rheumatoid Disease . A.L.M. Plus, Page 10 Newsletter Library, March 1988
Initial Evaluation of the Arthritis Patient Postgraduate Medicine, Vol. 80, No. 50, October, 1986
Pulmonary Infiltration in S.L.E. – Various Causes. Workshops in Rheumatology, Vol. 3, No. 5, 1982
Uncommon Causes of Septic Arthritis in S.L.E. – Rheumatology News, March, 1981
Arthritis in S.L.E., Question and Answer Format Workshops in Rheumatology, Vol. 2, No. 2, 1981
Bacterial Monarthritis Due to Neisseria Meningitides in S.L.E.,J. Rheumatol, 8:1 1981
Ongoing Study of Salivation Induced with Salivator in Sjogren’s Patients with Xerostomia – American Rheumatism Association National Meeting, Washington, D.C
Dermatomyositis and Atypical Mycobacteria Terrae Presenting as a Class Tenosynovitis, American Rheumatism Association December 1985, Savannah, GA
Induction of Saliva in Patients with Xerostomia, Secondary to Sjogren’s Syndrome, with Aide of a Salivator. Southeastern American Rheumatism Association.December 1985, Savannah, GA.
Comparison of Oral and Intramuscular Low Dose Methotrexate, International League of Rheumatism Meeting, May 1985, Sydney, Australia
Low Dose Pulse Methotrexate in Rheumatoid Arthritis, A Clinical Overview of 65. American Rheumatism Association Southeastern Meeting, 1984
Best Paper Presented – Thieves Market
S.L.E. and Immunosuppressive Therapy Complicated by StrongyloidesStercoralis, American Rheumatism Association Meeting, June 1981
Selective Values of CAT of the Brain in Cerebritis Due to S.L.E., American Rheumatology Meeting, June 1981 and International Rheumatology Meeting, June 1981.
Septic Arthritis in S.L.E., American Rheumatism Association, Southeastern Meeting, November 1980
- U3900s (IMPRESS) Genentech Roche, Rituximab MRI 60 patients 2006- 2012
- RA IND 9869 (PICS) UCB Cimzia Structural Outcomes Measurement 20 patients 2010-2013
- RA200802 BMS Abatacept Pilot MRI study 10 patients 2008-2010
- IM 101-006 BMS Assessment of Structural Benefits Of Abatacept as Measured by Low Field MRI n Patients with Rheumatoid Arthritis Who Have failed Prior TNF Therapy and Correlated with Clinical Outcomes as Measured by an Automated DAS 28 Scoring System 2010-2013 27 patients
- RA2013-01 Questcor The Effect of Corticotrophin (ACTH) in Combination with Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective as measured by a CDAI Score and Bone Edema, Synovitis and Erosions on MRI. 2013-ongoing 20 patients
- RA-012015 Pfizer An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) of Clinical Remission in Patients with Active Rheumatoid Arthritis (RA) as Measured from a Clinical and Structural Perspective when Treating to Target. 2015-ongoing 20 patients
- A Single Center, Observational, Noninterventional, Questionnaire Study to Evaluate Patient-reported Outcomes in Patients Receiving IV Therapy for Inflammatory Arthritis. PRO Assesment of Rheumatoid Arthritis Patients’ Experience with IV Administered Biology Therapy.
- Crescendo VIVID RA 2020-ongoing
- Vorso – Vorso PROTECT System 2020-ongoing
- Eli-Lilly SLE 2020-ongoing
- AbbVie AS Upadacitinib 2020-ongoing
- GKS RA Contrast 2020-ongoing
- BMS SLE JAK 2020-ongoing
- SetPoint- RA-vagal nerve implant device- 2018-ongoing
- BMS-SLE-JAK 2018-ongoing
- Janssen -SLE ustekinumab-2018 -2020
- AbbVie – PsA- ABT494- 2018-ongoing
- Novartis, CHOICE PsA secukinumab 2016- ongoing
- Amgen RA Biosimilar/Infliximab 2016-ongoing
- Ablynx SLE ALX-0061 2016-ongoing
- Sandoz RA GP2017/Humira 2016-ongoing
- Amgen RA Biosimilar/Rituximab 2016-ongoing
- Pfizer OA 2016-ongoing
- Eli Lilly AS 2016-ongoing
- Gilead RA Filgotinib 2016-ongoing
- Novartis AS secukinumab 2015-ongoing
- Astra Zeneca SLE 2-15-ongoing
- Amgen PsA 2015- ongoing
- Pfizer RA Tofacitinib/MTX/Adalimumab 2014-ongoing
- Pfizer- RA- Infliximab-Pfizer 2014 –ongoing
- Amgen PsA Enbrel 2014-ongoing
- Roche- RA 2013- ongoing
- Sanofi RA-2013 -ongoing
- Novartis PsA- 2013- ongoing
- Vertex RA 2012-2013
- Novartis RA 2011-2014
- Janssen RA IL6 (no MTX)2012-ongoing
- Janssen RA IL6 (MTX) 2013-ongoing
- Genentech SLE 2010-2012
- GSK (BLISS) SLE 2012-ongoing
- UCB SLE 2012-ongoing
- Pfizer (oral tablet) RA 2010-ongoing
- BMS RA Abatacept SC RA 2010-2014
- Centocor RA Go Save 2010-2013
- UCB certolizumab AS 2010-2013
- UCB certolizumab PsA 2010-ongoing
- Roche AS-2010-2012
- UCB RA-2010-2012
- Eli Lilly RA multiple trials 2011-2013
- Celgene PsA 2010-2012
- Cephalon SLE 2010-2012
- Eli Lilly SLE 2011-ongoing
- Takeda Gout with Cardiac Risk assessment 2011- 2012
- Rigel/AZ RA 2008-2012
- Human Genome 2008 Belimumab Lupus ongoing
- Incyte RA (oral tablet) 2009-2010
- BMS Abatacept RA 2008-2010
- Roche MRA RA 2008-2012
- BMS Abatacept SC, 2008-2010
- UCB Certolizumab RA 2008-2011
- Genentech- Rituxan Lupus 2007-2010
- Genentech 2007 Ocrelizumab RA 2010
- Centocor RA IV Golimumab 2007-2009
- Human Genome 2007 Belimumab Lupus
- TAP Febuxostat Gout 2007-2008
- Amgen Etanercept RA 2007-2008
- Amgen AMG 108 RA 2007
- Biogen BG9924 RA 2007-2009
- Abbott-RA Humira/MTX MRI 2007-2010
- Merrimack-RA alpha feta protein 2007-2008
- Centocor-2006-2012 RA Golimumab
- Savient-2006-2010 Gout Uricase Agent
- Novartis- OA Hip 2005-2006
- Celltech/UCB- CDP-870 RA 2005-2011
- Roche- RA-2005-2011 MRA
- Genentech- RA- Rituxan 2005-2012
- GSK- OA 2005
- DOV- Chronic Back Pain 2005
- BMS- Abatacept- Open label RA 2010
- Human Genome- 2005 Belimumab Lupus 2010
- Centocor- 2005-2012 Golimumab PsA
- Immunomedics- 2005-2005 SLE
- Human Genome Sciences – Belimumab RheumatoidArthritis 2004-2006
- Bristol-Myers-Squibb RA 2004-2011
- Sepracor –RA Insomnia 2004-2005
- Amgen Rheumatoid Arthritis 2003
- Pharmacia Rheumatoid Arthritis 2003
- MedImmune Rheumatoid Arthritis 2003-2005
- Genentech Rheumatoid Arthritis 2003-2009
- Human Genome Sciences Lupus Erythematosus 2003-2008
- TAP Gout Febuxostat 2003-2005
- Sanofi Shoulder Pain- 2003-2004
- Lilly Forteo-2003-2010
- Merck Cox 2 Safety 2002-2003
- Pharmacia Cox 2 Safety 2002
- Amgen Anakinra post market 2002-2003
- TAP Gout 2002-2004
- Alexion – Rheumatoid Arthritis-anti TNF 2002-2004
- Celecoxib – Searle – Osteoarthritis/Rheumatoid Arthritis 2000
- Cox-2 – Merck – Osteoarthritis Hip/Knee – 1999 – 2000
- Trocade – Roche – Rheumatoid Arthritis – 1999 – 2001
- Rofecoxib – Merck – Rheumatoid Arthritis – 1999-2000
- Celecoxib – Searle – Osteoarthritis/Rheumatoid Arthritis – 2000
- P & G – Osteoarthritis – 1999 – 2003
- Valdecoxib – Searle Osteoarthritis/Rheumatoid Arthritis 2000 – 2003
- Cox-2 – Merck – Osteoarthritis Knee – 1999 – 2000
- Infliximab – Centocor- Rheumatoid Arthritis Post Market 1999-2000
- Abbott Humira Rheumatoid Arthritis – 2000 – Ongoing
- Celecoxib – Searle – Osteoarthritis – 1998
- Celecoxib – Searle – Osteoarthritis Hip – 1997
- Celecoxib – Searle – Osteoarthritis Knee – 1997
- Celecoxib – Searle – Rheumatoid Arthritis – 1997
- Dry Mouth – Pharmaco – 1997
- Tenidap – Rheumatoid Arthritis – Pfizer – 1995-1997
- Salagen – Sjogren’s Syndrome – 1995 – 1996
- Risedronate – Osteoporosis – Proctor Gamble – 1993 – 1999
- Benoxaprofen – Rheumatoid Arthritis – Eli Lilly – 1979
- Ridaura – Methotrexate – Smith Kline Beecham – 1988
- Nabumetone – Smith Kline Beecham – 1991
- Salitron Salivary Gland Stimulation Biosonic Inc. – 1988 – 1992 Sjogren’s Study
- Therafectin – Quintiles – 1987
- Diclofenac NA – Ciba Geigy – 1984 – 1987
- Ridaura – Methotrexate – Smith Kline Beecham – 1980 – 1981
American Medical Association
American College of Physicians
American College of Rheumatology
International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR)
Florida Society of Rheumatology
Florida Medical Association
OFFICE ADDRESS: 21097 NE 27th Court
Suite 200
Aventura, Florida 33180
Phone : (305) 652-6676
Facsimile : (305) 932-6335
WEB SITE: www.rheum-care.com
E-mail : info@rheum-care.com
